Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Parkinson's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Parkinson's Disease. Browse Parkinson's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 9, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
256
Shown on this page
12
Current sort
Recently updated
Condition scope
Parkinson's Disease
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Parkinson's Disease studies are organized in the registry

Records generally use the registry spelling “Parkinson disease.” The portfolio mixes drug studies with a high share of device, exercise, and rehabilitation research, so the study-type filter is unusually useful here. Disease-stage language (“early,” “advanced,” “levodopa-treated”) commonly appears in titles.

Terms that often appear in related listings
early Parkinson deep brain stimulation levodopa gait

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Parkinson's Disease. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 85–96 of 256 matching trials for Parkinson's Disease.
Live ClinicalTrials.gov results.
Active filters: "levodopa" Clear condition filters
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569
View directory record Official record
Conditions
Parkinson Disease
Interventions
SAGE-217, Levodopa, Antiparkinsonian Agent(s)
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

NCT02549092
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

NCT02542696
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

NCT03781167
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

Social Decision Making in Parkinson's Disease

NCT04249544
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
45 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Not listed Phase 1 Interventional

Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease

NCT06021756
View directory record Official record
Conditions
Levodopa-Induced Dyskinesia, Parkinson's Disease
Interventions
Intervention: Ketamine
Drug
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Terminated Phase 4 Interventional Results available

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

NCT02549573
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms
Interventions
APOKYN, Physical Therapy
Drug · Behavioral
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

NCT01770145
View directory record Official record
Conditions
Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
Interventions
APOKYN, L-dopa, Trimethobenzamide
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Selegiline to Zelapar Switch Study in Parkinson Disease Patients

NCT00640159
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Zelapar
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
La Jolla, California • Sunnyvale, California • Boca Raton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

NCT01839396
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 9, 2026, 2:00 AM EDT
Completed No phase listed Observational Results available

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

NCT03944785
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
XADAGO (safinamide)
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 9, 2026, 2:00 AM EDT

About this Parkinson's Disease clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Parkinson's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Parkinson's Disease.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Parkinson's Disease.